[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Apollomics Inc Cl A (APLM)

Apollomics Inc Cl A (APLM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 59,163
  • Shares Outstanding, K 2,196
  • Annual Sales, $ 8,500 K
  • Annual Income, $ -10,940 K
  • EBIT $ 0 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.53
  • Price/Sales 7.00
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.70 +58.68%
on 08/12/26
28.00 -5.36%
on 09/02/26
+9.25 (+53.67%)
since 07/31/26
3-Month
12.88 +105.75%
on 06/17/26
28.00 -5.36%
on 09/02/26
+12.30 (+86.62%)
since 06/02/26
52-Week
3.95 +570.38%
on 09/03/25
42.12 -37.08%
on 10/15/25
+22.29 (+529.45%)
since 09/02/25

Most Recent Stories

More News
Apollomics Announces $10 Million Private Placement Transaction

FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple...

APLM : 26.50 (-1.63%)
APLMW : 0.0138 (unch)
Apollomics Announces $10 Million Private Placement Transaction

FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology...

APLM : 26.50 (-1.63%)
APLMW : 0.0138 (unch)
Apollomics Regains Full Compliance with Nasdaq Listing Requirements

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...

APLM : 26.50 (-1.63%)
APLMW : 0.0138 (unch)
Apollomics Regains Full Compliance with Nasdaq Listing Requirements

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple...

APLM : 26.50 (-1.63%)
APLMW : 0.0138 (unch)
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia

FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...

APLM : 26.50 (-1.63%)
APLMW : 0.0138 (unch)
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia

FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple...

APLM : 26.50 (-1.63%)
APLMW : 0.0138 (unch)
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and...

APLM : 26.50 (-1.63%)
APLMW : 0.0138 (unch)
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than...

APLM : 26.50 (-1.63%)
APLMW : 0.0138 (unch)
Apollomics Inc. Announces $2.0 Million Bridge Financing

FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible...

APLM : 26.50 (-1.63%)
APLMW : 0.0138 (unch)
Apollomics Inc. Announces $2.0 Million Bridge Financing

Apollomics Inc. Announces $2.0 Million Bridge Financing...

APLM : 26.50 (-1.63%)
APLMW : 0.0138 (unch)

Business Summary

Apollomics Inc. is a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers. Apollomics Inc., formerly known as Maxpro Capital Acquisition Corp., is based in FOSTER CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 28.39
2nd Resistance Point 27.74
1st Resistance Point 27.34
Last Price 26.50
1st Support Level 26.29
2nd Support Level 25.64
3rd Support Level 25.24

See More

52-Week High 42.12
Fibonacci 61.8% 27.54
Last Price 26.50
Fibonacci 50% 23.04
Fibonacci 38.2% 18.53
52-Week Low 3.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.